Tempus AI and Recursion extend data deal, add RNA model license

Tempus AI, Inc. (NASDAQ: TEM) has extended its multi-year data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) through November 2029 and entered a separate agreement to license Recursion's RNA foundation model, according to a press release from Tempus.

The two companies first established their data partnership in 2023. As part of the extension, the parties amended the financial terms of their original agreement, replacing discretionary license fees that could have totaled $84 million over two years with committed payments of $42 million over three years.

Under the new agreement, Recursion has granted Tempus a non-exclusive, worldwide license to its proprietary RNA sequencing model, known as "TxFM."

Ryan Fukushima, CEO of Data & Apps at Tempus, said: "We are thrilled to extend our collaboration with Recursion beyond the initial committed period, demonstrating the ongoing value of this partnership."

You May Also Be Interested In

• Rubico prices $8.5M convertible note offering on Nasdaq
• Scinai closes $4M private placement and warrant inducement
• ImmunityBio reports 3-year bladder preservation data for Anktiva plus BCG